Therapeutic Asset Ratings

3,774 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Zamtocabtagene Autoleucel Lymphoma	Miltenyi Biomedicine GmbH	P2	CCC (53)
cd19-ucart T-Cell Leukemia	Beijing Boren Hospital	P1	CCC (53)
cd22 car-transduced t cells Precursor B-Cell Acute Lymphoblastic Leukemia	National Cancer Institute (NCI)	P1	CCC (53)
cd22 car-transduced t cells B-Cell Chronic Lymphocytic Leukemia	National Cancer Institute (NCI)	P1	CCC (53)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Acute Lymphoblastic Leukemia	David Wald	P1/2	CCC (53)
Anti-Cd19/20-Car Vector-Transduced T Cells B Cell Lymphoma	University Hospital, Basel, Switzerland	P1/2	CCC (53)
Anti-Gd2-Car Engineered T Cells Neuroblastoma	Shenzhen Geno-Immune Medical Institute	P1/2	CCC (53)
Chimeric Antigen Receptor Modified T Cells Infusion AML	Peking University People's Hospital	P1/2	CCC (53)
gpc3-car-t cells Hepatocellular Carcinoma	RenJi Hospital	P1/2	CCC (53)
Tisagenlecleucel Chronic Lymphocytic Leukemia	Benjamin Tomlinson	P1/2	CCC (53)
Cart-19 Cells Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P3	CCC (52)
Cart-19 Cells Follicular Lymphoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P3	CCC (52)
Cart-19 Cells Mantle Cell Lymphoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P3	CCC (52)
LOVOTIBEGLOGENE AUTOTEMCEL Sickle Cell Disease	Genetix Biotherapeutics Inc.	P3	CCC (52)
ALLOGENEIC HUMAN UMBILICAL CORD BLOOD Hodgkins Lymphoma	Leland Metheny	P2	CCC (52)
Ari-0001 Follicular Lymphoma	GUSTAVO SALGUERO	P2	CCC (52)
Axicabtagene Ciloleucel Lymphoma	The First Affiliated Hospital of Xiamen University	P2	CCC (52)
cd22 car-transduced t cells Lymphoma	Liping Dou	P2	CCC (52)
Cord blood (plasma depleted) Ischemic Stroke	StemCyte, Inc.	P2	CCC (52)
Dc-Cik Renal Cell Carcinoma	Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus	P2	CCC (52)
e7 tcr-t cells Cervical Cancer	Christian Hinrichs	P2	CCC (52)
Ebv-Specific T Cells: B Epstein-Barr Virus-Associated Lymphoproliferative Disorder	Ciusss de L'Est de l'Île de Montréal	P2	CCC (52)
Hmscs Alzheimer Disease	Bernard (Barry) Baumel	P2	CCC (52)
Hpc, Cord Blood Hodgkins Lymphoma	Memorial Sloan Kettering Cancer Center	P2	CCC (52)
Human Dopaminergic Progenitor Cells Parkinson Disease	iRegene Therapeutics Co., Ltd.	P2	CCC (52)

Showing 426 to 450 of 3,774 assets

PreviousPage 18 of 151Next